Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Outlook Therapeutics appointed Kevin Lundquist as Chief Financial Officer, effective September 1, 2026, bringing over 20 years of experience in pharmaceutical and medical technology finance to the role as the company prepares for the U.S. commercial launch of LYTENAVA. Outgoing CFO Lawrence Kenyon will step down on September 1 but will remain as a non-executive employee through the end of the month to ensure a smooth transition. The company issued an inducement grant to Mr.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.